CRH and vulva cancer: Given that inhibitors specific to the various CRH family peptides have already been developed, demonstrating peripheral expression of CRH and related peptides in the aforementioned lesions, would partly justify the experimental use of such inhibitors in the treatment of vulvar premalignant conditions and vulvar cancer.